In the FEATHER Study, febuxostat, an XOR inhibitor, did not improve renal function compared with placebo in patients with CKD and hyperuricemia; however, subgroup analyses showed that it significantly reduced renal function decline in patients without proteinuria and in patients with serum creatinine levels below the median [124]. The gene discussed is XDH; the disease is hyperuricemia.